Skip to main content
Article thumbnail
Location of Repository

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

By Bhumsuk Keam, Seock-Ah Im, Sae-Won Han, Hye Seon Ham, Min A Kim, Do-Youn Oh, Se-Hoon Lee, Jee Hyun Kim, Dong-Wan Kim, Tae-You Kim, Dae Seog Heo, Woo Ho Kim and Yung-Jue Bang
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1995). A: Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial.
    2. (1981). A: Reporting results of cancer treatment. Cancer
    3. (2006). A: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    4. (2004). AL: Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.
    5. (2000). AL: Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.
    6. (2005). AR: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
    7. (2005). Bang YJ: Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci
    8. (2005). C: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.
    9. (2002). Cvitkovic E, de Gramont A: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    10. (2004). Danenberg PV: Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res
    11. (2004). DC: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res
    12. (2004). DC: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    13. (2003). DW: Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer.
    14. (2004). E: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    15. (2005). E: Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
    16. (2006). Feng JF: Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidinebased chemotherapy.
    17. (2002). G: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
    18. (2004). HJ: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    19. (1993). HJ: A phase III randomized study of 5-fluorouracil and cisplatin vs 5-fluorouracil, doxorubicin, and mitomycin C vs 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer
    20. (2001). HJ: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res
    21. (2002). HJ: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.
    22. (2001). HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    23. (2001). HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.
    24. (2004). Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.
    25. (2008). Identification and functional analysis of single nucleotide polymorphism in the tandem repeatBMC Cancer
    26. (1998). Leichman L: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
    27. (1995). Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res
    28. (1996). Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
    29. (2004). McLeod HL: Cancer pharmacogenetics.
    30. (2001). Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res
    31. (2001). Nexo BA: Polymorphisms of the DNA repair gene XPD: correlations with risk of basal cell carcinoma revisited. Carcinogenesis
    32. (2005). NK: Pharmacogenomic analysis to predict relapse in curatively resected gastric cancer patients treated with adjuvant 5-fluorouracil/cisplatin (FP) chemotherapy. Proc Am Soc Clin Oncol
    33. (2004). Palliative chemotherapy for advanced gastric cancer. Ann Oncol
    34. (2003). PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer
    35. (2006). Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
    36. (2003). Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev
    37. (2006). Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients.
    38. (1982). PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol
    39. (2005). Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res
    40. (2004). RD: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics
    41. (1999). Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science
    42. (2000). Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev
    43. (1982). Tables of the number of patients required in clinical trials using the log rank test. Stat Med
    44. (2003). Tagawa Y: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res
    45. (2005). Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.
    46. (2004). Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.
    47. (2005). toxicity in non-small cell lung cancer patients. Clin Cancer Res

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.